WO1994002452A1 - Benzene derivative - Google Patents
Benzene derivative Download PDFInfo
- Publication number
- WO1994002452A1 WO1994002452A1 PCT/JP1993/000961 JP9300961W WO9402452A1 WO 1994002452 A1 WO1994002452 A1 WO 1994002452A1 JP 9300961 W JP9300961 W JP 9300961W WO 9402452 A1 WO9402452 A1 WO 9402452A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- acceptable salt
- benzene derivative
- pharmacologically acceptable
- cholesterol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
- C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
Definitions
- the present invention relates to a benzene derivative or a pharmacologically acceptable salt thereof useful as a medicament.
- anti-lipidemia drugs which are effective in lowering blood lipids, especially cholesterol, have been mainly used for prevention and treatment of arteriosclerosis, but no definitive drug has yet been found.
- various studies are being conducted on arteriosclerosis and its preventive and therapeutic agents.
- ACAT acyl C0A: cholesterol 0-acyltransferase
- ACAT is also known to be involved in the intestinal absorption of cholesterol.
- cholesterol mixed into bile and released into the intestinal tract by dietary cholesterol and the adaptation of the living body itself is first absorbed from the intestinal tract as free cholesterol, and then esterified by the action of ACAT to form chylomicrons. After being filled, it is released into the bloodstream.
- the present inventors have paid attention to this ACAT, and have shown an inhibitory activity on ACAT in the arterial wall and intestinal tract. He has been conducting research for many years. As a result, as described later, they have found that a specific benzene derivative or a pharmacologically acceptable salt thereof achieves the intended purpose, thereby completing the present invention.
- the compound of the present invention is a benzene derivative represented by the following general formula (I) or a pharmacologically acceptable salt thereof.
- R 1 is a carboxyl group which may be protected or a formula
- R 5 is a lower alkyl group or a hydroxyalkyl group
- R 6 is a hydrogen atom or a hydroxyl group
- R 2 represents a hydrogen atom, a lower alkyl group, a hydroxyalkyl group or a carboxyalkyl group
- R 3 and R 4 are each a hydrogen atom or a hydroxyl group
- p is an integer of 1 to 6. ].
- the compound of the present invention represented by the above general formula (I) has an action of specifically inhibiting ACAT, which is one of the enzymes involved in the formation of foam cells,
- ACAT is one of the enzymes involved in the formation of foam cells.
- the compounds of the present invention can suppress the onset and progress of arteriosclerosis.
- the present invention provides an ACAT inhibitor comprising a benzene derivative represented by the above general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient; For example, it relates to an agent for preventing and treating arteriosclerosis.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a prophylactically or therapeutically effective amount of a benzene derivative represented by the above general formula (I) or a pharmacologically acceptable salt thereof and an excipient;
- the present invention relates to a method for treating a disease wherein a therapeutically effective amount of a benzene derivative represented by the above general formula (I) or a pharmacologically acceptable salt thereof is administered to a patient suffering from the disease.
- the lower alkyl group found in the definitions of R 2 and R 5 is a straight-chain or branched alkyl group having 1 to 6 carbon atoms, for example, a methyl group, an ethyl group, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, 2-methylbutyl, n- Hexyl group, isohexyl group, 2-methylpentyl group, 3-methylpentyl group, 2,2-dimethylbutyl group, 2,3-dimethylbutyl group, 3,3-dimethylbutyl group, 2-ethylbutyl group, 3-ethylbutyl group, 1-ethyl-1-methylpropyl group, 1-ethyl-2-methylpropyl group
- the carboxyl group which may be protected in the definition of R 1 is a free carboxyl group or a lower alkyl group represented by, for example, a methyl group, an ethyl group, and the like, 2, 2, 2-trichloro group Lower alkylalkyloxyalkyl groups, such as alkyl halide groups such as ethyl group, 2-iodoethyl group, and trichloromethyl group, bivaloyloxymethyl group, 1-acetoxethyl group, 2-acetoxethyl group, and 3-phthalaziryl group And a carboxyl group protected by a heterocyclic group. Still further, various acid amides can be included in the protected carboxyl group. In short, the protected carboxyl group may be any group as long as it can be decomposed in vivo by some means to become a carboxyl group.
- the hydroxyalkyl group found in the definitions of R 2 and R 5 means the above-mentioned lower alkyl group in which any one of the carbon atoms has 1 to 2 hydroxyl groups.
- Manufacturing method 1 The compound represented by the general formula (I) can be produced by the following method ⁇
- An aniline form represented by (III) is obtained, and a urea form is obtained from the aniline form ( ⁇ ) by an ordinary method.
- the urea form (IV) can be obtained from the aniline form (III) by a commonly used method, but is preferably a method comprising reacting aniline form (III) with sodium cyanate in acetic acid / water, for example, tetrahydrofuran.
- a method in which the aniline compound (III) is reacted with an isocyanate in a solvent that does not participate in the reaction is preferably a method comprising reacting aniline form (III) with sodium cyanate in acetic acid / water, for example, tetrahydrofuran.
- the target compound (I) can be obtained by condensing the obtained urea compound (IV) with a compound represented by the general formula (X) by a usual method.
- the condensation is preferably performed in the presence of sodium iodide and potassium carbonate.
- the reaction solvent for the condensation any solvent not involved in the reaction can be used, and preferably, dimethylformamide and the like can be mentioned.
- the reaction temperature is preferably about 80 degrees.
- the compound represented by the general formula (I) can also be produced by the following method.
- the compound represented by the general formula (VI) and the compound represented by the general formula (X) are condensed by an ordinary method to obtain a compound represented by the general formula (VII).
- the indicated compound is subjected to catalytic hydrogenation to obtain an aniline derivative represented by the general formula ( ⁇ ), and a target compound (I) is obtained from the aniline derivative (VIII) by a usual method.
- the reaction solvent is preferably dimethyl dimethylformamide, which can use any solvent not involved in the reaction.
- the compound represented by the general formula (VII) obtained here is catalytically hydrogenated by an ordinary method to obtain a compound represented by the general formula (VIII).
- Pum-carbon catalysts can be mentioned.
- the target compound (I) is preferably prepared by reacting the aniline compound (VIII) with sodium cyanate in acetic acid / water, or in a solvent not involved in the reaction such as tetrahydrofuran. By reacting VIII) with isocyanate, it can be obtained from the resulting aniline derivative represented by the general formula (VIII).
- “pharmacologically acceptable salt” is not limited.
- ACAT inhibitory activity of representative compounds of the present invention was measured using the in vitro test method described in FJ Field and SN Mathur (Journal of Lipid Research, Vol. 24, pp 1049-1059 (1983)). .
- any of the homogenate supernatant was used as an enzyme source, a radiolabeled O Reoiru C o A ( By measuring the amount of radiolabeled cholesterol oleate formed from cholesterol and comparing the measurement results of the control (when no test compound was added) and the case where the test compound was added, the oleoyl C 0 The ability of the test compound to inhibit acylation based on the fact that the test compound has an action of inhibiting an enzyme that catalyzes the acylation of cholesterol by A was evaluated.
- Table 1 shows the results. The data is shown in Table 1. IC 5 . The value, ie, the concentration of the test compound required to inhibit 50% of the ACAT enzyme activity.
- the compounds of the present invention have an ACAT inhibitory action. Therefore, the compounds of the present invention are effective as therapeutic agents for diseases for which ACAT inhibition is effective. That is, the compound of the present invention is useful as an agent for preventing or treating various arteriosclerosis. In particular, it is effective as a prophylactic / therapeutic agent for diseases caused by arteriosclerosis such as cerebrovascular disorders such as stroke and myocardial infarction. In addition, the compounds of the present invention have low toxicity and high safety, and thus the value of the present invention is high in that sense.
- the compound of the present invention When administered to a patient as an anti-atherosclerotic agent, it may be orally administered as a powder, granule, capsule, syrup, or the like, or as a suppository, injection, external preparation, or infusion. It may be administered parenterally.
- the dosage varies significantly depending on symptoms, age, etc., but is usually about 0.1 mg to 500 nig, preferably 2 mg to 1000 mg per adult per day, divided into 1 to several times a day. Administer.
- the drug product When formulating a drug product, the drug product is manufactured by a usual method using a normal drug carrier.
- an oral solid preparation when an oral solid preparation is prepared, the preparation is obtained after adding an excipient of the base drug and, if necessary, a binder, a disintegrant, a lubricant, a coloring agent, a flavoring agent, etc. to the base drug.
- the resulting mixture is made into tablets, coated tablets, granules, powders, capsules, etc. in a conventional manner.
- Excipients include, for example, lactose, corn starch, sucrose, glucose, sorbitol, crystalline cellulose, silicon dioxide, and the like. , Gelatin, shellac, hydroxypropylcellulose, hydroxypropylmethylcellulose, calcium citrate, dextrin, pectin, etc., as lubricants, for example, magnesium stearate, talc, polyethylene glycol, silica, Hardened vegetable oils, etc. are permitted to be added to pharmaceuticals as coloring agents, but flavoring agents such as cocoa powder, heart-shaped brain, aroma-san, heart-shaped oil, dragon brain, keich powder, etc. Is used.
- Tablets and granules prepared using these may be coated with sugar coating, gelatin coating, or the like, if necessary.
- a pH adjuster, buffer, stabilizer, solubilizer, etc. are added to the main drug, if necessary, and the resulting mixture is subcutaneously, intramuscularly, or intravenously according to a conventional method. Injectable.
- N-butyl-N '— (2,4-dihydroxy-6-methylphenyl) perylene 1 g (4.2 marl ol) was dissolved in dimethylformamide 5 ml, and potassium carbonate 1.45 g (10.5 mmol), 1 — (3-chloropropyl) — 5-ethyl — 4-phenylimidazole 5 ml of a solution of 1.04 g (4.2 mi0l) of dimethylformamide and a catalytic amount of sodium iodide were added. The resulting mixture was stirred at 80 ° C for 2 hours.
- reaction mixture was neutralized with dilute hydrochloric acid, and extracted with ethyl acetate.
- the ethyl acetate phase was washed with water and dried over anhydrous magnesium sulfate, and then ethyl acetate was distilled off under reduced pressure.
- ⁇ ( ⁇ ) 1.25 (3 ⁇ , t, J-7Hz) 1.48 -1.64 (4 ⁇ , m) 2.28 (311, s)
- 6-Methylphenyl] perylene 35 Omg (0.6 Ommol) was dissolved in methanol 1 Oral, and sodium borohydride 34 mg (0.9 Oramol) was added under ice-cooling, and the resulting mixture was allowed to stand at room temperature. Stir for 2 hours. After decomposing and neutralizing excess sodium borohydride with dilute hydrochloric acid, the obtained mixture was extracted twice with ethyl acetate.
- 6-Methylphenyl] perylene (4.5 g, 8.2 mmol) was dissolved in ethanol (10 Oral), and potassium hydroxide (1.4 g, 24.6 nraol) was added. The obtained mixture was refluxed for 1 hour, neutralized with dilute hydrochloric acid under ice cooling, and extracted twice with ethyl acetate. The ethyl acetate phase was washed with water and dried over anhydrous magnesium sulfate, and the ethyl acetate was distilled off under reduced pressure. The residue was purified by silica gel column chromatography (haze: dichloromethane-methanol) and recrystallized from ethyl acetate to obtain 2.9 g of the title compound. Yield 78.6%.
- the ethyl acetate phase was extracted with an aqueous solution of sodium hydrogen carbonate, and the mixture was statically separated and separated.
- the aqueous phase was removed, made acidic with diluted hydrochloric acid, and the acidic aqueous phase was extracted twice with ethyl acetate.
- the ethyl alcohol phase was washed with water and dried over anhydrous magnesium sulfate, and then ethyl acetate was distilled off under reduced pressure. The residue was recrystallized from ethyl acetate to obtain 120 mg of the title compound. Yield 3.2%.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93914989A EP0609457B1 (en) | 1992-07-20 | 1993-07-12 | Benzene derivative |
DE69314929T DE69314929T2 (de) | 1992-07-20 | 1993-07-12 | Benzolderivate |
JP50267694A JP3612328B2 (ja) | 1992-07-20 | 1993-07-12 | ベンゼン誘導体 |
US08/182,061 US5462958A (en) | 1992-07-20 | 1993-07-12 | Benzene derivatives and method of treating arteriosclerosis with benzene derivatives |
FI941300A FI941300A0 (fi) | 1992-07-20 | 1994-03-18 | Bentseenijohdannaiset |
NO940984A NO940984L (no) | 1992-07-20 | 1994-03-18 | Benzen-derivater |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4/213242 | 1992-07-20 | ||
JP21324292 | 1992-07-20 | ||
JP4/283432 | 1992-09-30 | ||
JP28343292 | 1992-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994002452A1 true WO1994002452A1 (en) | 1994-02-03 |
Family
ID=26519683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1993/000961 WO1994002452A1 (en) | 1992-07-20 | 1993-07-12 | Benzene derivative |
Country Status (10)
Country | Link |
---|---|
US (1) | US5462958A (ja) |
EP (1) | EP0609457B1 (ja) |
JP (1) | JP3612328B2 (ja) |
CN (1) | CN1084164A (ja) |
AT (1) | ATE159715T1 (ja) |
CA (1) | CA2115915A1 (ja) |
DE (1) | DE69314929T2 (ja) |
FI (1) | FI941300A0 (ja) |
HU (1) | HUT67475A (ja) |
WO (1) | WO1994002452A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0773218A1 (en) * | 1995-11-13 | 1997-05-14 | Mitsubishi Chemical Corporation | N-(Piperazinylalkoxyphenyl)-N'phenylalkylurea derivatives as ACAT inhibitors for the treatment of atheroschlerosis |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0592950A (ja) * | 1990-09-25 | 1993-04-16 | Eisai Co Ltd | ベンゼン、ピリジン若しくはピリミジン誘導体 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE792187A (fr) * | 1971-12-03 | 1973-03-30 | Sumitomo Chemical Co | Nouveaux derives d'alkylamines |
GB2056968A (en) * | 1979-08-21 | 1981-03-25 | Fujisawa Pharmaceutical Co | Piperazine derivative, processes for the preparation thereof and pharmaceutical composition comprising the same |
GB2062622A (en) * | 1979-11-07 | 1981-05-28 | American Cyanamid Co | Aniline Derivatives |
IT1168008B (it) * | 1981-07-31 | 1987-05-20 | Zambon Spa | Imidazol-eteri ed ester, procedimenti per prepararli e composizioni farmaceutiche che li contengono |
US4623662A (en) * | 1985-05-23 | 1986-11-18 | American Cyanamid Company | Antiatherosclerotic ureas and thioureas |
IL67417A (en) * | 1982-01-26 | 1989-10-31 | American Cyanamid Co | Antiatherosclerotic substituted ureas,process for their preparation and pharmaceutical compositions containing them |
US4722927A (en) * | 1986-04-28 | 1988-02-02 | Warner-Lambert Company | Pyrimidine amides of oleic or linoleic acid, composition containing them and their use as inhibitors of acyl-CoA cholesterol acyltransferase |
US4716175A (en) * | 1987-02-24 | 1987-12-29 | Warner-Lambert Company | Saturated fatty acid amides as inhibitors of acyl-CoA:cholesterol acyltransferase |
US4824843A (en) * | 1987-06-25 | 1989-04-25 | Warner-Lambert Company | Substituted amide inhibitors of cholesterol absorption |
ES2060682T3 (es) * | 1988-03-30 | 1994-12-01 | Warner Lambert Co | N-((fenil(2,6-disubstituido))-n'-aril)ureas como agentes antihipercolesterolemicos y antiateroscleroticos. |
IE892088L (en) * | 1988-07-12 | 1990-01-12 | William Henry Deryk Morris | Quinoline derivatives, their production and use |
WO1991004027A1 (en) * | 1989-09-15 | 1991-04-04 | Pfizer Inc. | New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat) |
CA2096970C (en) * | 1990-11-26 | 1998-07-14 | Masakazu Sato | Anilide derivative |
JPH05320143A (ja) * | 1992-03-18 | 1993-12-03 | Mochida Pharmaceut Co Ltd | 新規ピリミジン誘導体 |
-
1993
- 1993-07-12 DE DE69314929T patent/DE69314929T2/de not_active Expired - Fee Related
- 1993-07-12 AT AT93914989T patent/ATE159715T1/de not_active IP Right Cessation
- 1993-07-12 EP EP93914989A patent/EP0609457B1/en not_active Expired - Lifetime
- 1993-07-12 WO PCT/JP1993/000961 patent/WO1994002452A1/ja active IP Right Grant
- 1993-07-12 US US08/182,061 patent/US5462958A/en not_active Expired - Fee Related
- 1993-07-12 JP JP50267694A patent/JP3612328B2/ja not_active Expired - Fee Related
- 1993-07-12 CA CA002115915A patent/CA2115915A1/en not_active Abandoned
- 1993-07-12 HU HU9400795A patent/HUT67475A/hu unknown
- 1993-07-20 CN CN93108978A patent/CN1084164A/zh active Pending
-
1994
- 1994-03-18 FI FI941300A patent/FI941300A0/fi not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0592950A (ja) * | 1990-09-25 | 1993-04-16 | Eisai Co Ltd | ベンゼン、ピリジン若しくはピリミジン誘導体 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0773218A1 (en) * | 1995-11-13 | 1997-05-14 | Mitsubishi Chemical Corporation | N-(Piperazinylalkoxyphenyl)-N'phenylalkylurea derivatives as ACAT inhibitors for the treatment of atheroschlerosis |
US5807860A (en) * | 1995-11-13 | 1998-09-15 | Mitsubishi Chemical Corporation | Urea derivatives |
Also Published As
Publication number | Publication date |
---|---|
US5462958A (en) | 1995-10-31 |
EP0609457B1 (en) | 1997-10-29 |
CA2115915A1 (en) | 1994-02-03 |
ATE159715T1 (de) | 1997-11-15 |
HUT67475A (en) | 1995-04-28 |
FI941300A (fi) | 1994-03-18 |
CN1084164A (zh) | 1994-03-23 |
EP0609457A1 (en) | 1994-08-10 |
DE69314929T2 (de) | 1998-03-19 |
HU9400795D0 (en) | 1994-06-28 |
JP3612328B2 (ja) | 2005-01-19 |
EP0609457A4 (en) | 1994-08-24 |
DE69314929D1 (de) | 1997-12-04 |
FI941300A0 (fi) | 1994-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210403425A1 (en) | Tryptamine prodrugs | |
US20040266755A1 (en) | Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine | |
WO2017107864A1 (zh) | 苯并咪唑类衍生物、其制备方法和应用 | |
FR2530626A1 (fr) | Composes de carbostyryle | |
PT2203444E (pt) | Formas sólidas de 2-amino-3-(4-(2-amino-6-((r)-1-(4-cloro-2- (3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifluoroetoxi)- pirimidin-4-il)fenil)propanoato de (s)-etilo | |
WO2007088276A2 (fr) | Derives de sulfonamides, leur preparation et leur application en therapeutique | |
CA2267154A1 (fr) | Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant | |
NO300891B1 (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive forbindelser | |
WO2004043956A1 (fr) | Composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
HU218487B (hu) | N-Ciano-piridin-karboximid-amid-származékok, ilyen vegyületeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására | |
JPS63107958A (ja) | 新規なシクロオキシゲナ−ゼおよびリポキシゲナ−ゼ複合阻害剤 | |
EP0620221A1 (fr) | 5-Acylamino 1,2,4-thiadiazoles comme antagonistes ou agonistes de la cholécystokinine | |
HUT59923A (en) | Process for producing 4-substituted-dihydropyrido /4,3-d/pyrimidine derivatives and pharmaceutical compositions containing them as active components | |
CA3058687A1 (en) | Substituted imidazole salt compounds, preparation method therefor, pharmaceutical composition thereof, and applications thereof | |
IE45696B1 (en) | Derivatives of 2-(3-phenyl-2-aminopropionyloxy)-acetic acid | |
CA3240633A1 (en) | Tryptamine prodrugs | |
TW201124401A (en) | New phenoxypyrimidine derivatives | |
WO1994002452A1 (en) | Benzene derivative | |
JP3712529B2 (ja) | 3,3−ジピリジルアクリル酸アミド誘導体又はその薬学的に許容される塩 | |
CA2752198C (fr) | Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique | |
EP0234970B1 (fr) | Dérivés d'acylaminométhyl-3 imidazo[1,2-a]pyridines, leur préparation et leur application en thérapeutique | |
WO1997010214A1 (fr) | Nouveaux derives d'acide phenylacetique et compositions medicinales les contenant | |
JP4852416B2 (ja) | 環状ジアミン化合物及びこれを含有する医薬 | |
JP4560259B2 (ja) | ベンズイミダゾール化合物及びそれを含む医薬 | |
TW394768B (en) | Dithiolylidene acetamide derivatives and pharmaceutical compositions thereof for inhibiting the formation of advanced glycation end-products |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA FI HU JP KR NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2115915 Country of ref document: CA Ref document number: 1993914989 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 941300 Country of ref document: FI |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 08182061 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1993914989 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1993914989 Country of ref document: EP |